Author: Ken Dropiewski

Lombard Medical (LMT.L) Appoints Jonathan Hornsby As Vice President, Sales & Marketing

OXFORDSHIRE, England–(BUSINESS WIRE)–Lombard Medical, Inc. (NASDAQ: EVAR), a developer, manufacturer and marketer of endovascular aortic aneurysm repair products, today announced the appointment of Jonathan Hornsby as Vice President, Sales & Marketing, effective immediately. Jonathan Hornsby brings over 20 years of experience in the endovascular aortic repair business. He has been […]

Shockwave Medical Shows Off Disrupt BTK Lithoplasty System Study Results

FREMONT, Calif.–(BUSINESS WIRE)–Shockwave Medical, a pioneer in the treatment of calcified cardiovascular disease, today reported positive results from the DISRUPT BTK Study, which were presented at the annual Cardiovascular and Interventional Radiological Society of Europe (CIRSE) congress in Copenhagen, Denmark. DISRUPT BTK, a prospective single arm study, evaluated the use […]

BioCardia Announces Publication Of 12-Month Results From Phase II TRIDENT Clinical Trial That Shows Positive Safety Profile For Allogeneic Bone Marrow Stem Cells Delivered With Helix Transendocardial Delivery System

DALLAS & SAN CARLOS, Calif.–(BUSINESS WIRE)–BioCardia®, Inc. [OTC: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced 12-month results from the Phase II TRIDENT clinical trial, conducted by the University of Miami Miller School of Medicine and co-sponsored by the company. The results showed a […]

iVascular EffPAC 6 Months Outstanding Data Presented at CIRSE 2017 DCB Session

By Anastasia Perebeynos Copenhagen – September 18, 2017 – iVascular SLU data announced today, demonstrate the efficacy of the Luminor drug-coated balloon (DCB) in patients with peripheral arterial disease (PAD). The 6 months results from the full clinical cohort of the EffPAC randomized study were presented in the DCB session at the […]

Innovative implant for occlusion of heart defects

CARAG Completes CE Marking for its Breakthrough Carag Bioresorbable Septal Occluder (CBSO) Innovative bioresorbable implant of Carag removes risks associated with conventional metal frameworks and expands treatment options for patients with heart defects. CARAG AG, a privately held medical device development company, today announced that it has completed CE (Conformité […]

Boston Scientific (BSX) Announces Positive Late-Breaking Clinical Trial Data For The Heartlogic Heart Failure Diagnostic

DALLAS and MARLBOROUGH, Mass., Sept. 19, 2017 /PRNewswire/ — Boston Scientific (NYSE: BSX) today announced new data from the Multisensor Chronic Evaluation in Ambulatory Heart Failure Patients (MultiSENSE) study evaluating the performance of the HeartLogic Heart Failure Diagnostic to predict impending heart failure (HF) decompensation. Data from the study were presented as a late-breaking clinical […]

Cardihab Cardiac Rehab App Spun Out Of CSIRO Ehealth Division

BRISBANE, Australia–(BUSINESS WIRE)–An Australian solution to dramatically improve recovery from a heart attack today became reality. Cardihab’s technology platform was developed by scientists at the Australian eHealth Research Centre (AEHRC), a joint venture between CSIRO and the Queensland Government. Cardihab was spun-out from CSIRO after raising venture capital investment of […]

MiCell Has significant raise for MiStent

Micell raises $62m for MiStent SES SEPTEMBER 19, 2017 BY BRAD PERRIELLO, Drug Delivery Business News Micell Technologies said last week that it raised a debt-and-equity round worth nearly $62 million from a syndicate of 51 unnamed investors. Paris-based Micell makes the MiStent SES sirolimus-eluting absorbable polymer coronary stent, designed to treat coronary artery […]